Share this video  

BTOG 2021 | Inequalities in biomarker testing

Alastair Greystoke, MBChB, MSc, PhD, MRCP, Northern Institute for Cancer Research, Newcastle University, Newcastle, UK, talks on inequalities in access to biomarker testing and targeted treatments. Patients with lung cancer who were from a poorer socioeconomic background were found to have worse access to biomarker testing. This interview took place during the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.


Alastair Greystoke, MBChB, MSc, PhD, MRCP, has received consultancy and speaker fees from AstraZeneca, Amgen, Boehringer-Ingelheim, Bristol-Myers Squibb, Janssen/ J and J, Foundation Medicine, MSD, Novartis, Pfizer, Lilly, Takeda and Roche; and has received research funding from AstraZeneca.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter